Abstract
During neurogenesis, precursor cells undergo a defined number of divisions and terminally differentiate as postmitotic neurons. In the adult mammal, under certain conditions, postmitotic neurons re-enter the cell cycle and divide. The accumulated evidence demonstrates that the precise control of cell-cycle progression is critical for both neuronal development and maintenance of the neuronal phenotype. Cyclin-dependent Kinase Inhibitors (CDKIs) play the key role in this neuronal differentiation process of coordinating cell cycle exit and differentiation. Importantly, deregulation of the cell cycle leads to a variety of human neuronal diseases. In this review we discuss how regulation of neuronal progenitor proliferation and neuronal differentiation are coupled processes, based on evidence derived from the study of multiple animal models (mouse, Drosophila and Xenopus). In addition, we discuss the involvement of CDKIs in human neuronal diseases including cancers of neuronal systems, Alzheimer ’ s disease, and psychological disorders, and their potential as pharmacological targets.
Keywords: Cell cycle, G1/S phase, cyclin dependent kinase inhibitor, neuronal differentiation
Central Nervous System Agents in Medicinal Chemistry
Title: Regulators of the G1 Phase of the Cell Cycle and Neurogenesis
Volume: 7 Issue: 2
Author(s): Maryline Paris and Ourania M. Andrisani
Affiliation:
Keywords: Cell cycle, G1/S phase, cyclin dependent kinase inhibitor, neuronal differentiation
Abstract: During neurogenesis, precursor cells undergo a defined number of divisions and terminally differentiate as postmitotic neurons. In the adult mammal, under certain conditions, postmitotic neurons re-enter the cell cycle and divide. The accumulated evidence demonstrates that the precise control of cell-cycle progression is critical for both neuronal development and maintenance of the neuronal phenotype. Cyclin-dependent Kinase Inhibitors (CDKIs) play the key role in this neuronal differentiation process of coordinating cell cycle exit and differentiation. Importantly, deregulation of the cell cycle leads to a variety of human neuronal diseases. In this review we discuss how regulation of neuronal progenitor proliferation and neuronal differentiation are coupled processes, based on evidence derived from the study of multiple animal models (mouse, Drosophila and Xenopus). In addition, we discuss the involvement of CDKIs in human neuronal diseases including cancers of neuronal systems, Alzheimer ’ s disease, and psychological disorders, and their potential as pharmacological targets.
Export Options
About this article
Cite this article as:
Paris Maryline and Andrisani M. Ourania, Regulators of the G1 Phase of the Cell Cycle and Neurogenesis, Central Nervous System Agents in Medicinal Chemistry 2007; 7 (2) . https://dx.doi.org/10.2174/187152407780831675
DOI https://dx.doi.org/10.2174/187152407780831675 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia
Current Pharmaceutical Design Recent Approaches Targeting Beta-Amyloid for Therapeutic Intervention of Alzheimer's disease
Recent Patents on CNS Drug Discovery (Discontinued) BACE Inhibitors as Potential Drugs for the Treatment of Alzheimers Disease: Focus on Bioactivity
Recent Patents on CNS Drug Discovery (Discontinued) Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design Modulation of Sirtuins: New Targets for Antiageing
Recent Patents on CNS Drug Discovery (Discontinued) Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery Cholesterol, Alzheimers Disease, Prion Disorders: A menage a trois?
Current Drug Targets Morpho-Functional Features of In-Vitro Cell Death Induced by Physical Agents
Current Pharmaceutical Design Nanoparticles: A Neurotoxicological Perspective
CNS & Neurological Disorders - Drug Targets Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications
Current Drug Targets Recent Updates of N-Type Calcium Channel Blockers with Therapeutic Potential for Neuropathic Pain and Stroke
Current Topics in Medicinal Chemistry Common Cellular and Molecular Mechanisms Underlying Alzheimer’s Disease and Type 2 Diabetes: A Knowledge-Driven Approach
CNS & Neurological Disorders - Drug Targets Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters Levels of Estrogen Receptors α and β in Frontal Cortex of Patients with Alzheimers Disease: Relationship to Mini-Mental State Examination Scores
Current Alzheimer Research Role of Phase II Drug Metabolizing Enzymes in Cancer Chemoprevention
Current Drug Metabolism Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
Current Radiopharmaceuticals Induced Adaptive Resistance to Nitrooxidative Stress in the CNS: Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Molecular Mechanisms of Neurotoxicity of Pathological Prion Protein
Current Molecular Medicine Pharmacological Activation of LXRs Decreases Amyloid-β Levels in Niemann-Pick Type C Model Cells
Current Pharmaceutical Biotechnology